文献速递浆细胞疾病

del(17p)不伴TP53突变在强化治疗的新诊断多发性骨髓瘤中仍提示不良预后

del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.
PubMed 文献 · Blood · 2021-01-01

研究纳入121例浆细胞del(17p)比例>55%且接受统一强化治疗的新诊断多发性骨髓瘤患者,对TP53行深度靶向二代测序,并与2505例无del(17p)对照比较。结果显示「双打击」预后最差(中位生存36个月),但单独del(17p)亦预后不良(中位生存52.8个月对152.2个月)。

要点

  • del(17p)合并TP53突变(双打击)预后最差,中位生存36个月。
  • 单独del(17p)仍属高危,中位生存52.8个月,远低于无del(17p)者的152.2个月。
  • del(17p)本身即可作为不良预后的判断指标。

核心结论

  • del(17p)合并TP53突变的「双打击」患者预后极差,但单独del(17p)同样是高危特征,支持其作为不良预后指标。

研究设计与样本

  • 为验证既往小样本发现,研究纳入121例浆细胞del(17p)比例>55%、接受统一强化治疗的新诊断多发性骨髓瘤患者,行TP53深度靶向二代测序,并与2505例无del(17p)对照人群比较结局。

主要发现

  • 「双打击」患者中位生存36个月,预后最差。
  • 单独del(17p)患者中位生存52.8个月,对照组为152.2个月。
  • 结果证实单独del(17p)相较对照队列仍 confer 不良结局。

关键数值与推荐

  • del(17p)定义为>55%的浆细胞携带该缺失。
  • 双打击中位生存36个月;单独del(17p)中位生存52.8个月,无del(17p)对照152.2个月。

临床怎么用

  • 对del(17p)患者应行TP53测序识别双打击高危人群,单独del(17p)亦需按高危管理。

局限性

  • 患者均接受统一强化治疗,结论外推至其他治疗方案需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite tremendous improvements in the outcome of patients with multiple myeloma in the past decade, high-risk patients have not benefited from the approval of novel drugs. The most important prognostic factor is the loss of parts of the short arm of chromosome 17, known as deletion 17p (del(17p)). A recent publication (on a small number of patients) suggested that these patients are at very high-risk only if del(17p) is associated with TP53 mutations, the so-called "double-hit" population. To validate this finding, we designed a much larger study on 121 patients presenting del(17p) in > 55% of their plasma cells, and homogeneously treated by an intensive approach. For these 121 patients, we performed deep next generation sequencing targeted on TP53. The outcome was then compared with a large control population (2505 patients lacking del(17p)). Our results confirmed that the "double hit" situation is the worst (median survival = 36 months), but that del(17p) alone also confers a poor outcome compared with the control cohort (median survival = 52.8 months vs 152.2 months, respectively). In conclusion, our study clearly confirms the extremely poor outcome of patients displaying "double hit," but also that del(17p) alone is still a very high-risk feature, confirming its value as a prognostic indicator for poor outcome.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Corre J, Perrot A, Caillot D, et al. del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma. Blood. 2021. PMID: 33080624. doi:10.1182/blood.2020008346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。